GRI GRI Bio, Inc.
$1.90▼ -2.06%
Healthcare
Other
After hours
$1.90▼ -0.21%
Sep 11, 7:30 PM ET
Volume 131.7K
Avg Volume (10D) 1.05M
Key Metrics & Fundamentals
Market Cap
$4.15M
P/E Ratio
0.0
Div Yield
–%
52W Range
1.36 - 64.12
% vs 50 MA
9.45%
% vs 200 MA
-68.83%
RSI-14
49.9
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.97
Free Cash Flow
-$1.45M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$1.65M
COGS
–
Operating Exp
$1.65M
Operating Income
-$1.65M
EBIT
-$1.65M
Pretax Income
-$1.64M
Net Income
-$1.64M
EPS (Diluted)
-0.91
Price & Volume History
Loading chart…
Recent News
GRI Bio Presents New Phase 2a Data at ERS 2026 Defining GRI-0621's Mechanism of Action in IPF Across Nine Mechanistic Pillars
GlobeNewswire · Sep 8, 2026 12:15 PM
GRI Bio Featured in "Why Now" On-Demand Video Webcast
GlobeNewswire · Aug 27, 2026 1:01 PM
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GlobeNewswire · Aug 24, 2026 1:05 PM
GRI Bio Receives FDA Orphan Drug Designation for GRI-0621 to Treat Idiopathic Pulmonary Fibrosis
MT Newswires · Jun 18, 2026 12:48 PM
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
GlobeNewswire · Jun 18, 2026 12:31 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GRI's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.